A Cochrane review including two small, randomized trials «Tort S, Urrútia G, Nishishinya MB, et al. Monoamin...»1 measured the effectiveness of MAOIs in the treatment of fibromyalgia. The pooled effect on pain was -1.45 points (95 % confidence interval -2.71 to -0.20), translating to about -32 % decrease in pain.
Due to very small sample sizes, estimating the amount of harms is very uncertain.
The evidence was downgraded due to high risk of bias (two times) and imprecision.
| Reference | Study type | Population | Intervention and comparison | Outcomes | Risk of bias |
|---|---|---|---|---|---|
| RCT=randomized controlled trial; SR=systematic review; MA=meta-analysis; NMA=network meta-analysis; FIQ=Fibromyalgia impact questionnaire | |||||
| «Tort S, Urrútia G, Nishishinya MB, et al. Monoamin...»1 | SR/MA | Adults with fibromyalgia | MAOI vs placebo | Pain, adverse effects | High |
| Reference | Comments |
|---|---|
| «Tort S, Urrútia G, Nishishinya MB, et al. Monoamin...»1 | Dropout 30% and 40%. Second trial used on only per-protocol analysis. Evaluated adverse events included Dizziness, gastric discomfort, Headache, insomnia, nausea, pain increase, palpitations, discontinuations due to adverse events, depression. |
| Reference | Number of studies and number of patients | Follow-up time | Mean at follow up (sd) I | Mean at follow up (sd) C | Mean difference (95% CI) |
|---|---|---|---|---|---|
| Level of evidence: very low The quality of evidence is downgraded two times due to study limitations and once for imprecision. I= intervention; C=comparison; CI=confidence interval |
|||||
| «Tort S, Urrútia G, Nishishinya MB, et al. Monoamin...»1 | 2 studies | 4-12 weeks | - | 6,0 | -1.45 (-2.71 to -0) |